{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:22:24Z","timestamp":1790691744022,"version":"4.1.0"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"45","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["P400PM_199305"],"award-info":[{"award-number":["P400PM_199305"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["P2LAP3_184037"],"award-info":[{"award-number":["P2LAP3_184037"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiac magnetic resonance offers multiple facets in the diagnosis, risk stratification, and management of patients with myocardial diseases. Particularly, its feature to precisely monitor disease activity lends itself to quantify response to novel therapeutics. This review critically appraises the value of cardiac magnetic resonance imaging biomarkers as surrogate endpoints for prospective clinical trials. The primary focus is to comprehensively outline the value of established cardiac magnetic resonance parameters in myocardial diseases. These include heart failure, cardiac amyloidosis, iron overload cardiomyopathy, hypertrophic cardiomyopathy, cardio-oncology, and inflammatory cardiomyopathies like myocarditis and sarcoidosis.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehad510","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T16:41:34Z","timestamp":1690476094000},"page":"4738-4747","source":"Crossref","is-referenced-by-count":41,"title":["Cardiac magnetic resonance biomarkers as surrogate endpoints in cardiovascular trials for myocardial diseases"],"prefix":"10.1093","volume":"44","author":[{"given":"Dominik C","family":"Benz","sequence":"first","affiliation":[{"name":"Noninvasive Cardiovascular Imaging Section, Cardiovascular Division, Department of Medicine and Department of Radiology, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Gr\u00e4ni","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Antiochos","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiac MR Centre, University Hospital Lausanne , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobak","family":"Heydari","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Department of Medicine, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Colin","family":"Gissler","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Ge","sequence":"additional","affiliation":[{"name":"Terrence Donnelly Heart Center, St Michael\u2019s Hospital , Toronto , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A M","family":"Cuddy","sequence":"additional","affiliation":[{"name":"Noninvasive Cardiovascular Imaging Section, Cardiovascular Division, Department of Medicine and Department of Radiology, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Dorbala","sequence":"additional","affiliation":[{"name":"Noninvasive Cardiovascular Imaging Section, Cardiovascular Division, Department of Medicine and Department of Radiology, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8212-0759","authenticated-orcid":false,"given":"Raymond Y","family":"Kwong","sequence":"additional","affiliation":[{"name":"Noninvasive Cardiovascular Imaging Section, Cardiovascular Division, Department of Medicine and Department of Radiology, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"2024042022072716900_ehad510-B1","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/j.jcmg.2019.10.021","article-title":"Sudden cardiac death in ischemic heart disease: from imaging arrhythmogenic substrate to guiding therapies","volume":"13","author":"Gr\u00e4ni","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2024042022072716900_ehad510-B2","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur Heart J"},{"key":"2024042022072716900_ehad510-B3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12968-018-0484-5","article-title":"Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I\u2014analytical validation and clinical qualification","volume":"20","author":"Puntmann","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"key":"2024042022072716900_ehad510-B4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9149(02)02381-0","article-title":"Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy","volume":"90","author":"Grothues","year":"2002","journal-title":"Am J Cardiol"},{"key":"2024042022072716900_ehad510-B5","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2589-7500(20)30267-3","article-title":"Diagnosis and risk stratification in hypertrophic cardiomyopathy using machine learning wall thickness measurement: a comparison with human test-retest performance","volume":"3","author":"Augusto","year":"2021","journal-title":"Lancet Digit Health"},{"key":"2024042022072716900_ehad510-B6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12968-019-0575-y","article-title":"Machine learning in cardiovascular magnetic resonance: basic concepts and applications","volume":"21","author":"Leiner","year":"2019","journal-title":"J Cardiovasc Magn Reson"},{"key":"2024042022072716900_ehad510-B7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/ehjci\/jeaa329","article-title":"Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: the ESC EORP Cardiomyopathy\/Myocarditis Registry","volume":"22","author":"Mizia-Stec","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2024042022072716900_ehad510-B8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.hrthm.2017.10.003","article-title":"Cardiac magnetic resonance imaging using wideband sequences in patients with nonconditional cardiac implanted electronic devices","volume":"15","author":"Do","year":"2018","journal-title":"Heart Rhythm"},{"key":"2024042022072716900_ehad510-B9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/heartjnl-2017-311213","article-title":"Imaging as a surrogate marker of drug efficacy in cardiovascular disease","volume":"105","author":"Tarkin","year":"2019","journal-title":"Heart"},{"key":"2024042022072716900_ehad510-B10","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1016\/j.jacc.2016.03.508","article-title":"Effects of vitamin D on cardiac function in patients with chronic HF: the VINDICATE study","volume":"67","author":"Witte","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2024042022072716900_ehad510-B11","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0735-1097(00)01006-8","article-title":"Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure","volume":"36","author":"Groenning","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2024042022072716900_ehad510-B12","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1093\/eurheartj\/ehv390","article-title":"Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial","volume":"36","author":"Hamshere","year":"2015","journal-title":"Eur Heart J"},{"key":"2024042022072716900_ehad510-B13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"key":"2024042022072716900_ehad510-B14","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.jacc.2012.07.056","article-title":"Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide","volume":"60","author":"Chen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2024042022072716900_ehad510-B15","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1002\/ehf2.13645","article-title":"SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials","volume":"8","author":"Dhingra","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2024042022072716900_ehad510-B16","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41591-021-01452-0","article-title":"Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial","volume":"27","author":"Lewis","year":"2021","journal-title":"Nat Med"},{"key":"2024042022072716900_ehad510-B17","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1093\/eurheartj\/ehac363","article-title":"Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment","volume":"43","author":"Martinez-Naharro","year":"2022","journal-title":"Eur Heart J"},{"key":"2024042022072716900_ehad510-B18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2024042022072716900_ehad510-B19","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2024042022072716900_ehad510-B20","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1053\/euhj.2001.2822","article-title":"Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload","volume":"22","author":"Anderson","year":"2001","journal-title":"Eur Heart J"},{"key":"2024042022072716900_ehad510-B21","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1161\/CIRCULATIONAHA.109.874487","article-title":"Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major","volume":"120","author":"Kirk","year":"2009","journal-title":"Circulation"},{"key":"2024042022072716900_ehad510-B22","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis","volume":"107","author":"Pennell","year":"2006","journal-title":"Blood"},{"key":"2024042022072716900_ehad510-B23","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"key":"2024042022072716900_ehad510-B24","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood-2013-04-497842","article-title":"A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in \u03b2-thalassemia major (CORDELIA)","volume":"123","author":"Pennell","year":"2014","journal-title":"Blood"},{"key":"2024042022072716900_ehad510-B25","doi-asserted-by":"crossref","first-page":"e0192890","DOI":"10.1371\/journal.pone.0192890","article-title":"Role of T1 mapping as a complementary tool to T2* for non-invasive cardiac iron overload assessment","volume":"13","author":"Torlasco","year":"2018","journal-title":"PLoS One"},{"key":"2024042022072716900_ehad510-B26","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2024042022072716900_ehad510-B27","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1161\/01.CIR.102.8.858","article-title":"Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population","volume":"102","author":"Maron","year":"2000","journal-title":"Circulation"},{"key":"2024042022072716900_ehad510-B28","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1161\/CIRCULATIONAHA.117.027738","article-title":"Perspectives on the overall risks of living with hypertrophic cardiomyopathy","volume":"135","author":"Maron","year":"2017","journal-title":"Circulation"},{"key":"2024042022072716900_ehad510-B29","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024042022072716900_ehad510-B30","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.jacc.2019.08.1057","article-title":"Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry","volume":"74","author":"Neubauer","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024042022072716900_ehad510-B31","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jacep.2021.04.004","article-title":"Predictors of major atrial fibrillation endpoints in the National Heart, Lung, and Blood Institute HCMR","volume":"7","author":"Kramer","year":"2021","journal-title":"JACC Clin Electrophysiol"},{"key":"2024042022072716900_ehad510-B32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"2024042022072716900_ehad510-B33","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jcmg.2011.11.021","article-title":"Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy","volume":"5","author":"Green","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"key":"2024042022072716900_ehad510-B34","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.hrthm.2021.12.017","article-title":"Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: an international multicenter study","volume":"19","author":"Rowin","year":"2022","journal-title":"Heart Rhythm"},{"key":"2024042022072716900_ehad510-B35","doi-asserted-by":"crossref","first-page":"761860","DOI":"10.3389\/fcvm.2021.761860","article-title":"The impact of ischemia assessed by magnetic resonance on functional, arrhythmic, and imaging features of hypertrophic cardiomyopathy","volume":"8","author":"Aguiar Rosa","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2024042022072716900_ehad510-B36","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa025050","article-title":"Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy","volume":"349","author":"Cecchi","year":"2003","journal-title":"N Engl J Med"},{"key":"2024042022072716900_ehad510-B37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12968-021-00720-9","article-title":"Cardiovascular magnetic resonance predictors of heart failure in hypertrophic cardiomyopathy: the role of myocardial replacement fibrosis and the microcirculation","volume":"23","author":"Raphael","year":"2021","journal-title":"J Cardiovasc Magn Reson"},{"key":"2024042022072716900_ehad510-B38","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"2024042022072716900_ehad510-B39","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2024042022072716900_ehad510-B40","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"2024042022072716900_ehad510-B41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12968-020-00610-6","article-title":"Standardized image interpretation and post-processing in cardiovascular magnetic resonance\u20142020 update: Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post-Processing","volume":"22","author":"Schulz-Menger","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"key":"2024042022072716900_ehad510-B42","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2024042022072716900_ehad510-B43","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jaccao.2020.04.011","article-title":"Magnetic resonance imaging to detect cardiovascular effects of cancer therapy: JACC CardioOncology state-of-the-art review","volume":"2","author":"Harries","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2024042022072716900_ehad510-B44","doi-asserted-by":"crossref","first-page":"e012459","DOI":"10.1161\/CIRCIMAGING.121.012459","article-title":"Multiparametric early detection and prediction of cardiotoxicity using myocardial strain, T1 and T2 mapping, and biochemical markers: a longitudinal cardiac resonance imaging study during 2 years of follow-up","volume":"14","author":"Giusca","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"2024042022072716900_ehad510-B45","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00330-021-08260-7","article-title":"Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT","volume":"32","author":"Tahir","year":"2022","journal-title":"Eur Radiol"},{"key":"2024042022072716900_ehad510-B46","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jcmg.2020.09.039","article-title":"Serial cardiovascular magnetic resonance strain measurements to identify cardiotoxicity in breast cancer: comparison with echocardiography","volume":"14","author":"Houbois","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2024042022072716900_ehad510-B47","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ehjcvp\/pvab016","article-title":"Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial","volume":"8","author":"Kirkham","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024042022072716900_ehad510-B48","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2(2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"143","author":"Heck","year":"2021","journal-title":"Circulation"},{"key":"2024042022072716900_ehad510-B49","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","article-title":"Myocarditis and inflammatory cardiomyopathy: current evidence and future directions","volume":"18","author":"Tsch\u00f6pe","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2024042022072716900_ehad510-B50","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcmg.2021.11.017","article-title":"Multiparametric cardiovascular magnetic resonance approach in diagnosing, monitoring, and prognostication of myocarditis","volume":"15","author":"Eichhorn","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"2024042022072716900_ehad510-B51","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.jacc.2017.08.050","article-title":"Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis","volume":"70","author":"Gr\u00e4ni","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2024042022072716900_ehad510-B52","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2024042022072716900_ehad510-B53","doi-asserted-by":"crossref","first-page":"101159","DOI":"10.1016\/j.eclinm.2021.101159","article-title":"Symptom persistence despite improvement in cardiopulmonary health\u2014insights from longitudinal CMR, CPET and lung function testing post-COVID-19","volume":"41","author":"Cassar","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2024042022072716900_ehad510-B54","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jamacardio.2020.3557","article-title":"Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)","volume":"5","author":"Puntmann","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2024042022072716900_ehad510-B55","doi-asserted-by":"crossref","first-page":"e004262","DOI":"10.1161\/CIRCHEARTFAILURE.117.004262","article-title":"Cardiac magnetic resonance imaging in myocarditis reveals persistent disease activity despite normalization of cardiac enzymes and inflammatory parameters at 3-month follow-up","volume":"10","author":"Berg","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2024042022072716900_ehad510-B56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jctube.2017.02.001","article-title":"Histopathologic review of granulomatous inflammation","volume":"7","author":"Shah","year":"2017","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2024042022072716900_ehad510-B57","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jcmg.2016.05.009","article-title":"Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis","volume":"10","author":"Coleman","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"2024042022072716900_ehad510-B58","doi-asserted-by":"crossref","first-page":"e007488","DOI":"10.1161\/CIRCEP.119.007488","article-title":"Assessment of the 2017 AHA\/ACC\/HRS guideline recommendations for implantable cardioverter-defibrillator implantation in cardiac sarcoidosis","volume":"12","author":"Kazmirczak","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2024042022072716900_ehad510-B59","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamacardio.2022.2981","article-title":"Cardiovascular magnetic resonance imaging phenotypes and long-term outcomes in patients with suspected cardiac sarcoidosis","volume":"7","author":"Athwal","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2024042022072716900_ehad510-B60","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s12967-021-03130-8","article-title":"Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: anakinra randomized trial (MAGiC-ART)","volume":"19","author":"Kron","year":"2021","journal-title":"J Transl Med"},{"key":"2024042022072716900_ehad510-B61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12350-016-0682-1","article-title":"The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis","volume":"24","author":"Lee","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"2024042022072716900_ehad510-B62","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s00259-018-4001-8","article-title":"Prognostic role of serial quantitative evaluation of 18F-fluorodeoxyglucose uptake by PET\/CT in patients with cardiac sarcoidosis presenting with ventricular tachycardia","volume":"45","author":"Muser","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/45\/4738\/57294173\/ehad510.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/45\/4738\/57294173\/ehad510.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T18:07:59Z","timestamp":1713636479000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/45\/4738\/7272417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":62,"journal-issue":{"issue":"45","published-online":{"date-parts":[[2023,9,13]]},"published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehad510","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,1]]},"published":{"date-parts":[[2023,9,13]]}}}